Recent News

• 06.10.2026 - Final Report: A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Pregnant Participants Living with HIV and Their Inf
• 06.10.2026 - A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
• 06.05.2026 - A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventative Medications
• 05.21.2026 - B3461077

Recent Filings

• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2026 - 13F-HR Quarterly report filed by institutional managers, Holdings
• 05.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.05.2026 - 8-K Current report
• 05.05.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.01.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.27.2026 - 4 Statement of changes in beneficial ownership of securities